SCHEDULE: StemPoint Capital Discloses 8.4% Stake in Xilio Therapeutics
Beneficial Ownership Disclosure
StemPoint Capital LP, along with its general partner and Michelle Ross, has disclosed an 8.4% beneficial ownership stake in Xilio Therapeutics, Inc., comprising common stock and warrants.
Summary
- StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons") have jointly filed an Amendment No. 1 to Schedule 13G.
- The Reporting Persons beneficially own an aggregate of 6,030,028 shares of Xilio Therapeutics, Inc. common stock.
- This ownership represents 8.4% of the issuer's outstanding common stock.
- The beneficially owned amount includes 2,030,028 shares of common stock, 2,000,000 pre-funded warrants, and 2,000,000 Class A warrants.
- The percentage of class is calculated based on 67,540,930 shares outstanding as of January 2, 2026, as reported in the Issuer's Form 8-K filed on January 5, 2026, plus the shares acquirable through warrants, subject to a 9.9% beneficial ownership limitation.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, except for activities solely related to a nomination under Rule 240.14a-11.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral disclosure. A significant institutional stake can be seen positively, but the filing explicitly states no intent to influence control, making it a routine ownership update.
Industry Context
StockSavvy.ai notes that this Schedule 13G filing primarily concerns a change in beneficial ownership disclosure and does not provide information relevant to broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: The disclosure of a significant 8.4% stake by an institutional investor group could be viewed as a vote of confidence, potentially influencing market perception.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Date of event which requires filing of this statement. |
| 2026-01-02 | Date as of which the amount beneficially owned is reported and the basis for outstanding shares calculation. |
| 2026-01-05 | Date of Issuer's Form 8-K filing reporting 67,540,930 shares outstanding. |
| 2026-02-17 | Date of signing of the Joint Filing Agreement and the Schedule 13G. |
Keywords
Xilio Therapeutics, StemPoint Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Equity Stake, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.